Esperion Therapeutics, Inc. (NASDAQ:ESPR) Short Interest Update

Esperion Therapeutics, Inc. (NASDAQ:ESPR) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 32,350,000 shares, a growth of 27.0% from the December 15th total of 25,470,000 shares. Based on an average daily trading volume, of 5,630,000 shares, the days-to-cover ratio is presently 5.7 days. Approximately 16.6% of the shares of the stock are sold short.

Esperion Therapeutics Trading Down 2.2 %

Shares of ESPR stock traded down $0.05 on Friday, reaching $2.21. 2,549,121 shares of the company’s stock were exchanged, compared to its average volume of 5,249,790. Esperion Therapeutics has a 52 week low of $1.58 and a 52 week high of $3.94. The stock has a market capitalization of $435.46 million, a PE ratio of -3.45, a P/E/G ratio of 0.17 and a beta of 1.03. The company’s fifty day simple moving average is $2.47 and its 200 day simple moving average is $2.18.

Institutional Investors Weigh In On Esperion Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ESPR. BOKF NA bought a new stake in shares of Esperion Therapeutics during the 2nd quarter worth approximately $26,000. Traphagen Investment Advisors LLC bought a new stake in shares of Esperion Therapeutics during the 3rd quarter worth approximately $27,000. Xponance Inc. bought a new stake in Esperion Therapeutics during the 2nd quarter valued at $28,000. Versor Investments LP bought a new stake in Esperion Therapeutics during the 3rd quarter valued at $44,000. Finally, American Century Companies Inc. bought a new stake in Esperion Therapeutics during the 2nd quarter valued at $50,000. 47.39% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on ESPR. Cantor Fitzgerald began coverage on Esperion Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $8.00 target price for the company. StockNews.com cut Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th. The Goldman Sachs Group began coverage on Esperion Therapeutics in a report on Wednesday, December 18th. They issued a “neutral” rating and a $4.00 target price for the company. HC Wainwright reiterated a “buy” rating on shares of Esperion Therapeutics in a report on Friday, January 10th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $6.00 target price on shares of Esperion Therapeutics in a report on Friday, December 13th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $7.30.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.